The Effect of Remotely Delivered Pilates on Physical , and Psychologic
Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?
What it found
No result yet.
What was tested
Treatment tested
- Pilates
What it measured
Main measures
Change from baseline in walking endurance (Six-Minute Walk Test distance)
Baseline and 16 weeks (end of treatment)
Walking and mobilityChange from baseline in walking speed (Timed 25-Foot Walk)
Baseline and 16 weeks (end of treatment)
Disability progressionWalking and mobilityChange from baseline in balance (Berg Balance Scale)
Baseline and 16 weeks (end of treatment)
Walking and mobilityChange from baseline in fatigue (Fatigue Severity Scale)
Baseline and 16 weeks (end of treatment)
FatigueChange from baseline in pain (Short-form McGill Pain Questionnaire)
Baseline and 16 weeks (end of treatment)
Pain
Other measures (6)
Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
Baseline and 16 weeks (end of treatment)
Thinking and memoryChange from baseline in verbal learning and memory (California Verbal Learning Test-II)
Baseline and 16 weeks (end of treatment)
Thinking and memoryChange from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
Baseline and 16 weeks (end of treatment)
Thinking and memoryChange from baseline in depression symptoms
Baseline and 16 weeks (end of treatment)
Mood and sleepChange from baseline in anxiety symptoms
Baseline and 16 weeks (end of treatment)
Mood and sleepChange from baseline in health-related quality of life
Baseline and 16 weeks (end of treatment)
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Age 18 years or older * Self-reported diagnosis of multiple sclerosis by a neurologist * Relapse-free for the past 30 days before screening * Able to speak and read English as the primary language * Access to the internet and e-mail, * Ability to use Zoom, and willingness to complete testing sessions and questionnaires * Ambulatory without an assistive device (for example, cane) * Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS) * Insufficiently active, defined as a score \< 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS) * Adequate visual ability and literacy to read materials printed in 14-point font * Currently treated with a disease-modifying therapy
Exclusion criteria
* Pregnant * Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Loading reviews and guidelines…
History
Started
Nov 2025
Main results due
Dec 2027
Finished
Dec 2027